Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06392789 · ClinicalTrials.gov registry record · NA

A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors

A NA study of Insomnia and Anatomic Stage III Breast Cancer AJCC v8, sponsored by University of Washington.

Active
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT06392789: Active NA study of Insomnia and Anatomic Stage III Breast Cancer AJCC v8, sponsored by University of Washington.

NCT06392789 is a NA study of Insomnia and Anatomic Stage III Breast Cancer AJCC v8 that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 60 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06392789, a NA study of Insomnia and Anatomic Stage III Breast Cancer AJCC v8, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This clinical trial evaluates the effect of conversational agent, Cecebot, on improving insomnia in stage I-III breast cancer survivors. Sleep disturbance ranks among the top concerns reported by breast cancer survivors and is associated with poor quality of life. Many breast cancer survivors also have decreased physical activity, which may also have a negative impact on sleep and quality of life. Cognitive behavioral therapy for insomnia (CBTi) and physical activity interventions have individually been reported to improve sleep and to have a positive impact on quality of life. Cecebot is a personalized short messaging service (SMS)-based behavioral intervention that combines CBTi and physical activity strategies that may improve sleep for breast cancer survivors.

Primary Outcome

Defined as the proportion of all treatment participants who permanently stop the intervention prior to week 6 for any reason. An all-cause discontinuation rate of 40% or less will be considered a threshold for acceptability.

Conditions Studied

Insomnia Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage I Breast Cancer AJCC v8

Interventions

  • OTHER Questionnaire Administration
  • OTHER Medical Device Usage and Evaluation
  • OTHER Internet-Based Intervention
  • BEHAVIORAL Cognitive Behavior Therapy for Insomnia
  • OTHER Text Message-Based Navigation Intervention

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-10-04
Est. Completion 2026-03-31
Phase NA
University of Washington

1,048 total trials

What the registry record for NCT06392789 still lists

NCT06392789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (65% lower).

The record links to 4 conditions, with Insomnia appearing as the primary indexed condition, and to 5 interventions - of which Questionnaire Administration is the first listed.

NCT06392789 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT06392789 about?

NCT06392789 is a clinical study titled "A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors". This clinical trial evaluates the effect of conversational agent, Cecebot, on improving insomnia in stage I-III breast cancer survivors. Sleep disturbance ranks among the top concerns reported by breast cancer survivors and is associated with poor quality of life. Many breast cancer survivors also h...

What is the current status of trial NCT06392789?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-10-04. Estimated completion is 2026-03-31.

What conditions does trial NCT06392789 study?

This clinical trial studies the following conditions: Insomnia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8.

What interventions are being tested in trial NCT06392789?

The interventions under investigation include: Questionnaire Administration (OTHER), Medical Device Usage and Evaluation (OTHER), Internet-Based Intervention (OTHER), Cognitive Behavior Therapy for Insomnia (BEHAVIORAL), Text Message-Based Navigation Intervention (OTHER).

Who is sponsoring clinical trial NCT06392789?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06392789 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06392789's enrollment target sits among peer trials

60 89th of 151 higher than 58 of 151 other Insomnia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06392789, the US trial registry maintained by the National Library of Medicine. NCT06392789 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.